|
|
Vaccine Detail
|
Recombinant Fowlpox-TRICOM Vaccine |
| Vaccine Information |
- Vaccine Name: Recombinant Fowlpox-TRICOM Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007162
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- CD58
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- ICAM1
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Cd80
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Description: This is for Prostate Cancer (NCT00450619). A vaccine comprised of a recombinant fowlpox virus vector encoding a TRIad of COstimulatory Molecules (B7-1, ICAM-1 and LFA-3) (TRICOM), which may enhance antigen presentation and activate cytotoxic T-cells. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it is replication incompetent in mammalian cells (NCI04) (NCIT_C2667).
|
| Host Response |
|
|
| References |
NCIT_C2667: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2667]
NCT00450619: [https://clinicaltrials.gov/ct2/show/NCT00450619?term=TRICOM+Vaccine&rank=1]
|
|
